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INTRODUCTION
The classical estrogen receptor, estrogen receptor ca (ERa) plays an important role in breast cancer development and a large fraction of ERcL positive breast cancers respond to treatment with tamoxifen. We have cloned a novel p21 activated kinase (PAK), termed PAK6, which binds to the androgen receptor (AR) and selectively to the 4-hydroxytamoxifen (OHT) liganded ERa. PAKs are a family of serine/threonine kinases that bind to and are regulated by the active (GTP bound) form of the Rho family small (p21) GTPases, Cdc42 and Rac. PAK6 is expressed in normal mammary epithelium and in breast cancer cell lines, and its expression may be modified in breast cancer. Taken together, these results support a role for PAK6 in breast cancer. The purpose of this research is to test the major hypothesis that PAK6, through interactions with the ERa, contributes to the development of breast cancer. A second hypothesis to be tested is that the OHT dependent ERa-PAK6 interaction contributes to the therapeutic effect of OHT in breast cancer and the subsequent development of OHT resistance. The specific aims are 1) to determine the structure, cellular distribution, and activation state of endogenous PAK6 protein in normal breast and breast cancer cell lines; 2) to determine whether PAK6 contributes to ERa function and cell growth in breast cancer cell lines; and 3) to determine whether PAK6 contributes to tamoxifen sensitivity in breast cancer BODY Over the past year we have completed and published the data on PAK6 cloning and on its interaction with the ERa (Lee et al., 2002, enclosed) . The data in this report also address aspects of PAK6 functional interaction with steroid hormone receptors.
Additional not yet published data relevant to each of the proposed tasks are detailed below. Task 1. Determine the structure, cellular distribution, and activation state of endogenous PAK6 protein in normal breast and breast cancer cell lines a. Develop PAK6 antibodies (months 1-12) b. Assess endogenous PAK6 using these antibodies (months 6-24) c. Clone and sequence endogenous PAK6 from breast cancer cell lines (months 1-12)
Rabbit polyclonal antibodies have been generated against PAK6 using a GST-PAK6 fusion protein. These antibodies recognize a single protein of 75 kDa in PAK6 transfected cells. The antibodies have been used to assess endogenous PAK6 protein expression in breast cancer cells. By immunoprecipitation and immunoblotting, the antibodies recognize a protein of approximately 75 kDa in MCF7 cells, consistent with PAK6. Interestingly, the antibodies also recognize a second band of approximately 65 kDa in MCF7 cells, but not in prostate cancer cells or in PAK6 transfected cells. Studies are ongoing using antibodies and cloning to determine whether this lower band represents an alternative form of PAK6. The antisera is also being affinity purified for immunohistochemistry on clinical breast cancer samples.
Task 2. Determine whether PAK6 contributes to ER% function and cell growth in breast cancer cell lines a. Develop anti-sense methods to downregulate PAK6 (months 6-24) b. Develop dominant negative PAK6 constructs (months 1-18) c. Assess the functional consequences of blocking PAK6 (months 12-36)
The initial efforts have been to develop dominant negative PAK6 constructs. By site directed mutagenesis we have generated vectors encoding PAK6 mutants that are constitutively active or kinase dead, as well as constructs that no longer bind Cdc42. In preliminary transient transfection studies these have inhibited androgen receptor function similarly to the wild type. Stable MCF7 cell transfectants expressing these mutant proteins have now been generated and are currently being examined functionally.
Task 3. Determine whether PAK6 contributes to tamoxifen sensitivity in breast cancer -5-a. Determine whether tamoxifen blocks PAK6 activation (months 18-30) b. Determine whether the tamoxifen-ERl-PAK6 complex mediates cell cycle arrest (months 12-24)
Although this task was proposed to be carried out later, we have generated MCF7 cell lines expressing increased levels of wild type and mutant PAK6 proteins. Using these cells, studies are being done to assess whether the PAK6 expression alters responses to tamoxifen. 
KEY RESEARCH ACCOMPLISHMENTS

CONCLUSIONS
During the past year we have completed and published our initial studies describing PAK6 and its interaction with the ERa and AR. Over the past year we have also generated a series of reagents that were needed to further address the functional significance of PAK6 and its interactions with steroid hormone receptors. These materials include PAK6 specific antibodies, mutants, and cell lines. Studies using these reagents to complete the tasks outlined above are in progress.
A human protein termed p21-activated kinase 6 transient transfections with episomal and inte-(PAK6), based on homology to the PAK family of grated reporter genes. AR inhibition was not reserine/threonine kinases, was cloned as an AR inversed by transfection with an activated Cdc42 teracting protein. PAK6 was a 75-kDa protein with mutant, Cdc42V12, which by itself also inhibited AR a predicted N-terminal Cdc42/Rac interactive bindtransactivation. Epitope-tagged PAK6 was primaring domain and a C-terminal kinase domain. PAK6
ily cytoplasmic in the absence or presence of AR bound strongly to GTP-Cdc42 and weakly to GTPand hormone. PAK6 transcripts were expressed Rac. In contrast to most PAKs, kinase activity was most highly in brain and testis, with lower levels in not stimulated by Cdc42 or Rac, but could be stimmultiple tissues including prostate and breast. ulated by AR binding. PAK6 interacted with the PAK6 interaction provides a mechanism for crossintact AR in a mammalian one-hybrid assay and talk between steroid hormone receptors and bound in vitro, without ligand, to the hinge region Cdc42-mediated signal transduction pathways and between the AR DNA-and ligand-binding domains, could contribute to the effects of tamoxifen in PAK6 also bound to the ERa, and binding was breastcancerandinothertissues.(MolecularEndoenhanced by 4-hydroxytamoxifen. AR and ERa crinology 16: 85-99, 2002) transcriptional activities were inhibited by PAK6 in THE AR is a steroid hormone receptor member of the p160 family of steroid receptor coactivator (SRC) the larger nuclear receptor family that mediates proteins (5-7). The SRC proteins appear to be the major the biological functions of androgens (1, 2). In addition coactivators mediating the ligand-dependent AF-2 to its physiological roles in many tissues, the AR also transactivation function of the LBD, through histone plays a central role in prostate cancer development acetyl or methyltransferase activity and association and progression (3, 4) . The steroid hormone receptors with cAMP response element binding protein or share a relatively conserved central DNA binding dop300. The SRC proteins can also interact directly main (DBD) and a C-terminal ligand binding domain with the N terminus of steroid hormone receptors, (LBD), which also has a ligand-dependent transactivaand this interaction may be particularly critical for tion function (referred to as AF-2). Their N-termini the AR (8-11). are more diverse, but generally possess an indepenIn addition to the p160 steroid receptor coactivator dent transactivation function (AF-1), with the AR Nproteins, there is a growing list of proteins that interact terminal domain being particularly large and having a with the N-terminal, DNA, or ligand binding domains of strong AF-1. Hormone binding causes conformational steroid hormone receptors (5, 6). These include prochanges that result in receptor dissociation from an teins linked to the general transcriptional machinery, HSP90 chaperone complex, homodimerization, and proteins that function as transcriptional coactivators or the generation of a binding site for proteins containing corepressors by other mechanisms, and proteins the leucine-x-x-leucine-leucine (LXXLL) motifs, including functions of which remain to be determined. Some of Abbreviations: ARE, Androgen response element; BIC, these interactions are regulated by ligand binding and bicalutamide; CDS, charcoal dextran-stripped; CRIB, Cdc mediated by LXXLL or related motifs, while others are 42/Rac interactive binding; DBD, DNA-binding domain; independent of ligand. There is also a ligand-depen-DHT, dihydrotestosterone; DTT, dithiothreitol; ERE. estrodent interaction between N-terminal and C-terminal gen response element; EST, expressed sequence tag; GFP, green fluorescent protein; GRIP, GR-interacting prodomains of the AR and other steroid hormone receptein; GST, glutathione-S-transferase; LBD, ligand-binding tors, which appears to be particularly important for AR domain; mAb, monoclonal antibody; MBP, myelin basic transactivation (12-18). Finally, there is evidence for protein; MMTV-LTR, mouse mammary tumor virus-long nontranscriptional functions of steroid hormone reterminal repeat; NLS, nuclear localization signal; OHT, 4-hydroxytamoxifen; PAK, p21-activated kinase; SRC, steceptors (19-21) and an association between the ERa roid receptor coactivator.
and P13K (22).
This report describes the isolation and characteriza-56 and the GAL4 DBD-AR (505-919) fusion protein tion of an AR and ERa interacting protein termed p21-used in the yeast screen (Table 1) . This level of activated kinase 6 (PAK6), based upon its homology to induction was greater than that seen with a transpreviously identified PAKs. PAKs form an evolutionaractivation domain fused to GR interacting protein 1 ily conserved family of serine/threonine kinases that (GRIP1) (563-1121), which contains three LXXLL bind to, and are regulated by, the active (GTP-bound) motifs and an additional AR-interacting domain (48) . form of the Rho family small (p21) GTPases, Cdc42
In contrast, no induction was observed when clone and Rac (23) (24) (25) (26) (35- Complete sequencing of clone 56 revealed a consen-37), cell cycle regulation (38) , heterotrimeric G protein sus kinase domain at the C terminus, but no homology signaling (39) , and apoptosis (40) (41) (42) (43) . Therefore, the to previously reported proteins at the amino terminus AR-and ERa-PAK6 interactions provide potential di- (Fig. 1A) . However, the first 35 nucleotides of the cDNA rect links between these steroid hormone receptors insert (nucleotides 874-908, boxed in Fig. 1A ) were and signal transduction pathways regulating diverse identical to the 3'-end of an expressed sequence tag cellular functions.
(EST) from a testis cDNA library (GenBank accession no. AA815255), indicating that this EST encoded the 5'-end of clone 56. The plasmid containing this EST RESULTS was obtained and sequenced to provide the 5'-end of the transcript. The assignment of the initiation methiIsolation of a PAK-Related Kinase Interacting onine was based upon an in-frame stop codon (tga) 39 with the AR in Yeast bases upstream (Fig. 1A, boxed) . Since the overlap between the EST and clone 56 was only 35 bases A fragment of the human AR containing the DNA and immediately before a poly A tract in the EST, RT-PCR ligand binding domains (AR505-919), was fused to the was used to confirm that this EST represented the GAL4 DNA binding domain and used as the bait in a 5'-end of the clone 56 transcript. RT-PCR from prosseries of yeast two-hybrid screens, in the presence of tate cancer-derived cDNAs using 5'-primers derived 1 gIM dihydrotestosterone (DHT). Positive clones were from the EST and 3'-primers from clone 56 generated subsequently screened without DHT, and several a product of the predicted size and sequence (data not clones that showed strong DHT-dependent growth shown), confirming that EST AA815255 represented were isolated and sequenced. Two clones contained the 5'-end of clone 56. in-frame fusions to previously identified proteins, gelThe full-length sequence predicted a protein of 681 solin, an actin-binding protein (44) , and ARA70. ARA70 amino acids with a molecular mass of 75 kDa (Fig. 1A) . (fused at alanine 168) was identified previously as an Analysis of the full-length coding region revealed ho-AR interacting protein, although its functional signifimology at the 5'-and 3'-ends to the PAK family of cance remains unclear (45, 46) . The significance of the serine/threonine kinases, of which four had been pre-AR interaction with gelsolin was also unclear, although viously reported in humans (24, 37, 49-51). The sean AR interaction with another actin-binding protein, quences of two additional human PAK-related profilamin, was recently reported (47) .
Partial sequencing of a third isolate (clone 56) indicated that it was a novel protein. A specific interaction between the AR and clone 56 in yeast A ggcacgaggcctctcctcagcgcctaagagagaggcccagtgcgggf~gggagtcgcgaggaagaggcggaaggcgccggaaggcacc 88 
Fig. 1. Complete Sequence of PAK6 and Homology to Other PAKs
A, PAK6 nucleotide and predicted amino acid sequence. An in-frame stop codon (tga) 5' of the predicted initiation ATG and the N-terminal CRIB domain are boxed. Nucleotides at the 5'-end of yeast clone 56 that were identical to the 3'-end of the EST from a testis library (nucleotides 874-908) are also boxed. Amino acids highly conserved in all kinase domains are boxed. S531, which is an asparagine in most other kinases, is boxed and in bold. A possible heterotrimeric G protein-binding site is boxed at the C terminus. B, Homology in CRIB and autoinhibitory domains. The alignments are based on PAK6 with periods (.) indicating identical residues and dashes (-) marking gaps introduced to maximize homology. PAK1-3 have an N-terminal extension past the CRIB domain that is absent in PAK4-6. p-Strands (P1 and 02) and ty-helices (H1 -3) are from the PAMi crystal structure. Residues underlined in the CRIB domain mediate dimerization. The autoinhibitory lysine in PAK1-3 is indicated by an asterisk (*). ARE 4 -Luciferase mechanisms for regulating the kinase activity of these 14 latter PAKs. 12
The C terminus of PAK6 encoded a consensus kinase domain with homology to PAK1, 2, and 3 R 10 (50% compared with PAKI), but again with much L 8 greater homology to PAK4 (80% homology). Resi-U 6 dues highly conserved in kinase domains were also .4 conserved in PAK6 (Fig. 1A, boxed) , with the excep-2 tion of an asparagine that was replaced by a serine I-(S531), a replacement also seen in PAK4 (boxed and ing motifs were not present in PAK4, 5, or 6, as the (20 ng), as Indicated. DHT was added at 24 h, and cells were CRIB domains were at the extreme N terminus. harvested at 48 h and assayed for luciferase and Renilla
Three of the four residues defining a putative hetactivity.
erotrimeric G protein binding motif were present in the C terminus of PAK6 (Fig. 1A, boxed) .
teins, termed PAK5 and PAK6, were more recently Cell and Tissue Distribution of PAK6 deposited in GenBank. The protein isolated here was identical to PAK6, located on chromosome 15q15.
The full-length PAK6 was fused to the C-terminus of The N terminus of PAK6 had homology with the green fluorescent protein (GFP) and used to assess CRIB domains of the previously characterized PAKs, cellular distribution. The GFP-PAK6 fusion protein containing six of eight of the CRIB domain consensus transfected into HeLa cells localized primarily to the residues (Fig. 1 B) (27). The greatest homology was plasma membrane and cytoplasm ( Fig. 2A) . PAK6 rewith PAK4 (37) and PAK5, also with CRIB domains at mained primarily cytoplasmic when cotransfected with the immediate N terminus. The recently reported crysthe AR, in the absence (Fig. 2B ) or presence of DHT tal structure of human PAK1 indicated that this protein (Fig. 2D ). HeLa cells were similarly transfected with a formed a dimer through an antiparallel p-ribbon GFP-AR expression vector to assess PAK6 effects on formed by a P-strand that overlapped the CRIB do-AR distribution. The AR in HeLa cells was primarily main (p1 in Fig. 18 ) (52). The critical contact residues cytoplasmic in the absence of DHT (Fig. 2 , E and F) in this p-strand are conserved in PAK1-6 (underlined and nuclear in the presence of DHT (Fig. 2, G and H) . in the CRIB consensus in Fig. 1 B) , suggesting that This distribution was not altered by PAK6 cotransfec-PAK6 is similarly a dimer. The PAK1 crystal structure tion (Fig. 2, F and H) . Similar results were obtained also showed that the autoinhibition of PAKI kinase by indirect immunofluorescence with AR and an activity was due to a bundle of three helices (H1-3 in epitope-tagged PAK6, indicating that cellular localiza- Fig. 1 B) that packed against the kinase domain and tion was not altered by the GFP fusion (data not positioned a lysine residue (amino acid 141 in PAK1, shown). indicated with an asterisk) into the active site. These Hybridization of a unique internal fragment from structural features were highly conserved in PAK1-3, PAK6 (nucleotides 451-1256) to a human multiple tisbut were not evident in PAK4-6, suggesting alternative sue expression array revealed the strongest expresWhole brain, cerebral cortex, frontal lobe, parietal lobe, occipital lobe, temporal lobe, paracentral gyrus of the cerebral cortex, pons. Column 2 (A-H), Blank, right cerebellum, corpus callosum, amygdala, caudate nucleus, hippocampus, medulla oblongata, putamen. Column 3 (A-E), Substantia nigra, nucleus accumbens, thalamus, pituitary gland, spinal cord; F-H, blank. Column 4 (A-H), Heart, aorta, left atrium, right atrium, left ventricle, right ventricle, interventricular septum, apex of heart. Column 5 (A-H),
Esophagus, stomach, duodenum, jejunum, ileum, ileocecum, appendix, ascending colon. Column 6 (A-C), Transverse colon, descending colon, rectum; D-H, blank. Column 7 (A-H), kidney, skeletal muscle, spleen, thymus, peripheral blood leukocyte, lymph node, bone marrow, trachea. Column 8 (A-H), Lung, placenta, bladder, uterus, prostate, testis, ovary, blank. Column 9 (A-F), Uver, pancreas, adrenal gland, thyroid gland, salivary gland, mammary gland; G and H, blank. Column 10 (A-H), Promyelocytic leukemia (HL-60), HeLa S3, chronic myelogenous leukemia (K-562), lymphoblastic leukemia (MOLT-4), Burkitt's lymphoma (Rail), Burkitt's lymphoma (Daudi), colorectal adenocarcinoma (SW480), lung carcinoma (A549). Column 11 (A-H), Fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen, fetal thymus, fetal lung, blank. ............................ sion in testis and in many areas of the brain, particuand data not shown), likely reflecting competition for larly cortical structures (Fig. 21) . Lower level expression transcription factors by the noninteracting VP16 transwas seen in prostate, thyroid, adrenals, placenta, kidactivation domain. In contrast, cotransfection with the ney, esophagus, mammary gland, and heart. There VP16-PAK6(256-681) vector increased the induction was little or no detectable expression in ovary, uterus, to 175-fold. These results indicated that PAK6 interintestine, liver, lung, spleen, thymus, peripheral blood acted with the intact ligand-bound AR on DNA in leukocytes, lymph node, or bone marrow. (Fig. 3) . Cotransfection with vectors enof nuclear receptors including the AR (48, 57) . AR coding only the VP16 activation domain (AASWP16)
binding to the GST-GRIP1(624-1 122) fusion protein or a VP16-SRC1(595-780) fusion, containing the first was detectable, but was very weak (Fig. 4A) . Binding LXXLL motif of SRC-1, were used as negative controls was not enhanced by DHT, which may reflect nonnaas this region of SRC-1 was shown previously to intive folding of the in vitro-generated AR. In contrast, teract very weakly or not at all with the AR (1 0, 11, 16 ).
full-length AR was precipitated efficiently by the GSTBoth vectors markedly repressed AR activity (Fig. 3 PAK6(256-681) fusion protein. S-labeled ERa in the presence of 10 nM E2 (E 2 ), 20 tm PAK6 binding was specific for the AR . 3 S-Labeled or 100 gLM OHT, or no added hormone. B, GST, GST-GTPCdc42V12, or GST-ERa(281-595) were used to pull down ERa, generated by in vitro transcription/translation in full-length 35 S-labeled PAK6, in the presence or absence of rabbit reticulocyte lysates, bound specifically to the the indicated hormones.
positive control GST-GRIP(624-1122) fusion protein (Fig. 5A ). This GRIP1 binding in the absence of added estrogen likely reflected estrogen in the rabbit reticuindependent as it did not require added DHT and was locyte lysate and could be augmented with added E2. not blocked by bicalutamide (BIC), a competitive anAs expected, ERa binding to GST-GRIP1(624-1122) tagonist of DHT binding and AR function (58).
was markedly reduced by the partial agonist 4-GST-PAK6(256-681) pull-down experiments were hydroxytamoxifen (OHT). A comparable level of ERa next carded out using the endogenous AR from LNCaP binding to GST-PAK6(256-681) was observed in the cells, the only generally available AR-expressing human absence or presence of E2. However, in marked conprostate cancer cell line. LNCaP cells express a mutant trast to GST-GRIP1 results, ERa binding to PAK6 was AR (T877A) that still responds to DHT but has altered enhanced (3.4-fold) by OHT (Fig. 5A ). This latter finding responses to other ligands and AR antagonists (59) .
was consistent with the AR results and indicated that LNCaP lysates were precipitated by GST-PAK6(256-PAK6 bound to a site distinct from the agonist-gener-681), GST-GRIP1(624-1122), or control GST beads, and ated LXXLL coactivator binding site, as this site is AR was detected by immunoblotting. The results simioccluded in the OHT-bound ERa (60-62). larly demonstrated specific binding of the intact AR to It was next determined whether full-length PAK6 PAK6 (Fig. 4B) . In these experiments comparable bindbound specifically to the ERa. These experiments ing to the GST-GRIP1 (624-1122) control was observed, used a GST-ERa(281-595) fusion protein, encompossibly reflecting native folding and androgen binding passing the region C terminal to the NLS and the by the AR in vivo. The hormone dependence of binding complete ERa LBD, and shown previously to bind by the LNCaP AR was further assessed by culturing the LXXLL containing coactivator proteins in an agonistcells overnight in medium with charcoal dextran-stripped dependent manner (63). Full-lengthin vitro-transcribed/ (CDS) FCS (steroid hormone-depleted medium), or with translated PAK6 bound specifically to the GSTadded DHT (10 nM) or BIC (5 WM), which is also an ERa(281-595) fusion protein in the absence of added antagonist of the LNCaP AR. GST-PAK6(256-681) E2, and binding was not augmented by added E2 bound specifically to the AR from DHT, BIC, and un- (Fig. 5B) . Moreover, consistent with the results above, treated (CDS) LNCaP cells (Fig. 40) , further demonstratbinding was enhanced (2.7-fold) by OHT. PAK6 binding that binding was not ligand dependent.
ing by the OHT-ligated GST-ERa was comparable to the CRIB domain-mediated binding of GST-GTPCdc42V12 (see below). A, GST fusion proteins were used to pull down myc-tagged body (mAb) (Fig. 6A) . In contrast, only very weak PAK6 from a transfected CVl cell lysate. Equivalent amounts binding to GST-GTP-RacV12 was detected, alof GST fusion proteins loaded with GTP were used as indithough this binding appeared to be specific as no cated, and precipitated PAK6 was detected by immunoblotbinding was detected to either an inactive control ting with an anti-myc mAb. GST-CD1 d is an irrelevant control (GST-RacN1 7) or to other control GST proteins, fusion protein. Lysate alone (2% of the material used for each GTP-Cdc42 or -Rac binding activates the kinase pull down) is shown in the first lane, and the position of the activity o other PAKs by blocking an autoinhibitory full-length PAK6 (75 kDa) is indicated. B, PAK6 programmed i oor unprogrammed rabbit reticulocyte lysates (PAK6 +/-, domain carboxy to the CRIB domain (Fig. 1 B) (52, respectively) were pulled down with the Indicated AR or GTP-64-66). However, this domain appears to be absent in loaded GST fusion proteins. The precipitates were then split PAK4-6 (see Fig. 1B ), and PAK4 kinase activity is not in half and analyzed for kinase activity with MBP substrate stimulated by Cdc42 (37) . Therefore, kinase assays (top panel), or analyzed for bound 3 5 S-PAK6 (bottom panel).
PAK6 Interaction with p21 GTPases
A
were carried out to assess PAK6 activation by GTPCdc42. For these experiments, full-length
S-labeled PAK6 was expressed in vitro and precipitated by a binding GTP-Cdc42 vs. GTP-Rac. The results further series of GST fusion proteins bound to glutathione indicated that PAK6 kinase activity was not regulated beads. The kinase activity of the precipitated proteins by Cdc42 binding, with the data suggesting instead a was compared with proteins precipitated by the same role for AR in regulating PAK6 kinase activity. beads from a control unprogrammed rabbit reticulocyte lysate, using myelin basic protein (MBP) as a PAK6 Inhibition of AR and ERa substrate. No kinase activity was detected in the GSTTranscriptional Activity GTP-Cdc42V12 precipitate (Fig. 6B, top panel) , although PAK6 binding to these beads was confirmed Cotransfection experiments were carried out to deterby recovery of the labeled PAK6 protein (Fig. 6B, bot- mine whether PAK6 could modulate the transcriptional tom pane/). There was also no detectable kinase acactivity of the AR. Cells were cotransfected with an tivity or PAK6 binding to GST-Rac fusion proteins.
ARE 4 -luciferase reporter plasmid, AR expression vecKinase activity was precipitated by the GSTtor (pSVARo) (67), pcDNA-PAK6 or control (pcDNA-AR(505-919) fusion protein from the unprogrammed LacZ) expression vectors, and an internal control Reand PAK6 programmed lysates (Fig. 613) . However, the nilla vector (pRL-SV40). AR transcriptional activity was kinase activity from the PAK6 programmed lysate was stimulated 33-fold by DHT in the absence of PAK6 and consistently greater (-3-fold). This indicated that it was not inhibited by the control pcDNA-LacZ vector reflected PAK6 kinase activity, or possibly PAK6 acti- (Fig. 7A) . In contrast, AR transcriptional activity was vation of another AR-associated kinase, stimulated by markedly inhibited by PAK6, with Induction reduced AR binding. It is not yet clear whether the lower levels approximately 5-fold by 200 ng of the PAK6 vector. of kinase activity precipitated from the unprogrammed This inhibition was not a nonspecific effect on tranlysate were due to an endogenous PAK or other kiscription or on the pSV promoter regulating the AR, as nases. Taken together, these results demonstrated expression of the control Renilla reporter regulated by that the PAK6 CRIB domain was functional with rea pSV promoter was unaffected by PAK6 (Fig. 7B ). spect to p21 binding, with a marked preference for
Immunoblotting for AR protein further showed that the approximately 6-fold in these cells (Fig. 8B ). This was reduced to 2.4-fold induction by cotransfection with PAK6, indicating that PAK6 could inhibit AR activity on inhibition was not due to decreased AR protein exan integrated as well as an episomal reporter. pression (Fig. 7C) .
Similar cotransfection experiments were carried out The effect of PAK6 on transcription from another with an ERa expression vector and an estrogen re-AR-responsive promoter, the mouse mammary tumor sponsive element (ERE)-regulated luciferase reporter virus long terminal repeat (MMTV-LTR) containing two plasmid to determine whether PAK6 modulated ERa steroid response elements recognized by the AR, was transcriptional activity. Luciferase activity was stimunext examined. DHT stimulated AR transcriptional aclated about 4.5-fold by E2 (Fig. 9A) . Cotransfection tivity on the MMTV-LTR-luciferase reporter by 5.3-fold with PAK6 reduced this stimulation by approximately (Fig. 8A) . Similar to the above result with the ARE 4 50%, while a control LacZ vector had no effect. This reporter, this DHT-stimulated activity was inhibited by result demonstrated a similar inhibitory effect of PAK6 cotransfection with PAK6. It was also determined on AR and ERa transcriptional activity. whether PAK6 affected AR transcriptional activity in As PAK6 also binds to GTP-Cdc42, it was possible the more physiological setting of an integrated ARE.
that AR and ERa inhibition by PAK6 was due to seFor this experiment, MVl cells were stably transfected questration of GTP-Cdc42 rather than a direct interwith the MMTV-LTR-luciferase reporter plasmid, in action. This was addressed by cotransfection with conjunction with a neomycin resistance plasmid. activated (GTPase-deficient) Cdc42V12. DHT stimu-G418-resistant clones were then screened for ligandlated AR transactivation by 26-fold, and this was re- Cdc42 sequestration by the PAK6 CRIB domain, as it luciferase reporter (100 ng), pRL-SV40 (0.2 ng), pcDNA-ERa was not reversed by cotransfected Cdc42V12. More-(200 ng), and pcDNA-LacZ or pcDNA-PAK6 expression vecover, Cdc42V12 by itself inhibited AR transcriptional tors. Luciferase and Renilla activities were assessed after activation. This latter result was consistent with a pre-24 h ± E2 (10 nM). B, CV1 cells were transfected and treated vious report showing that Rho GDIa, a negative regas in Fig. 7 , with the addition of a pCDNA-Cdc42Vl 2 expresulator of Rho GTPases, could augment AR, ERa, ERf3, sion plasmid as indicated. Results in this experiment were not and GR transcriptional activity, and that the ER was corrected for Renilla, as Cdc42V12 at the high concentration inhibited by Rho, Rac, and Cdc42 (68). Taken todecreased Renilla activity. gether, these results suggest that the AR transcriptional inhibition by PAK6 could be due to recruitment duced to approximately 7-fold by PAK6 (Fig. 9B) . of Cdc42 to the AR complex. However, PAK6 is unThis repression by PAK6 was not reversed by colikely to mediate all of the effects of Rho GTPases on transfected Cdc42V12. Moreover, transfection of steroid hormone receptors, as it interacted only Cdc42V12 by itself inhibited AR transcriptional weakly with GTP-Rac. activity, consistent with a recent report that Rho Alternatively, PAK6 inhibition of the AR may be meGTPases can negatively regulate steroid hormone diated by phosphorylation of the AR or other ARreceptors (68 (78, 79) , and the in response to activation of other signal transduction failure of GTP-Cdc42 to activate PAK6 kinase activity. pathways.
PAK6 binding may be a mechanism through which diAlternative functions for the PAK6-AR interaction verse signal transduction pathways, in particular those may be to recruit PAK6 and/or activate its kinase mediated through Cdc42, can modulate the activity of activity. The kinase activity of most previously characthe AR and ERa (and possibly other nuclear receptors). terized PAKs is blocked by an autoinhibitory domain Alternatively, or in addition, PAK6 binding may mediate that follows the CRIB domain (52, 64-66). Cdc42 or nontranscriptional functions of the AR or ERa. Finally, Rac binding relieves this inhibition and results in PAK while the OHT-enhanced PAK6-ER% interaction may or autophosphorylation and activation of kinase activity.
may not be physiological, it could contribute to the theraAlthough PAK6 clearly has a functional CRIB domain, peutic effects of OHT in breast cancer and in other which selectively binds to Cdc42, there is limited hotissues. mology between PAK6 and human PAK1-3 in the CRIB-regulated autoinhibitory domain (see Fig. 1 B) , and PAK6 kinase activity is not activated by GTPCdc42 binding. The N terminus of PAK6 is homolo-MATERIALS AND METHODS gous to PAK4, which also selectively binds to Cdc42 and is not activated by Cdc42 binding (37) . as indicated, were constructed by PCR and confirmed by DNA sequencing. pGAD24-GRIP(563-1121) was from Michael Stallels of nuclear PAK6, alone or in association with AR, cup (University of Southern California, Los Angeles) (57). Liquid could not be ruled out. Preliminary biochemical fracp-galactosidase assays were carried out on extracts from transtionation studies similarly indicate that PAK6 is mostly formed yeast containing an integrated GAL4 promoter regulatcytoplasmic but suggest that a small fraction might be ing P-galactosidase (strain HF7c) (CLONTECH Laboratories, nsof PAK6 expression were in Inc.) with O-nitrophenyl-f-D-galactopyranoside as the subnuclear. The highest levels ofPK xrsinwr n strate, as described by the manufacturer. brain and testis, although PAK6 could also be expressed at relatively high levels by specific cell types in PAK6 Expression Vectors other tissues. While this manuscript was under revision, another group similarly identified PAK6 as an Full-length PAK6 was assembled from three fragments in the AR-interacting protein that was highly expressed in pcDNA3.1(-)/Myc-His C mammalian expression vector, contestis and could repress AR transcriptional activity, taining C-terminal myc and histidine epitope tags (Invitrogen, although their data indicated marked AR stimulated Carlsbad, CA). The 5'-end through an internal Xbal site was nuclear translocation of transfected PAK6 (76) . It is obtained from the I.M.A.G.E. consortium plasmid described above, a middle fragment from the Xbal site to a downstream clear that specific antibodies will be needed to better BamHI site was generated by PCR amplification from prosassess the cellular and tissue distribution of the entate cancer cDNA, and a fragment from the BamHI site to the dogenous protein.
3'-end was from the yeast clone 56. The pcDNA 3.1 epitope Database searches have not revealed definite hotag (myc-his) was placed in frame at the C terminus by cutting at a Blpl site in the PAK6 stop codon and a downstream KpnI mologs of PAK6 in other species. However, the site in the pcDNA polylinker, followed by blunting with mung mushroom bodies tiny (mbt) gene from Drosophila bean nuclease and ligation. encodes a PAK that appears related to human
The GFP-PAK6 vector (pEGFP-PAK6) was constructed in PAK4, 5, and 6 (77). Mutations in mbt interfere with the pEGFP-C1 vector (CLONTECH Laboratories, Inc.). An brain development, which in conjunction with the oligonucleotide encoding the first 11 amino acids of PAK6 with a C-terminal BglIl site was ligated to the Bglll site enhigh level expression of PAK6 in human adult and coding amino acids 11 and 12 in PAK6. This was then exfetal brain, suggest a role for PAK6 in brain develcised and an N-terminal HindIll site introduced by the oligoopment. In this regard, a PAK3 mutation has been nucleotide was used to ligate PAK6 In frame at the C terminus identified in a family with mental retardation (51) .
of GFP as a HindIIl-KpnI fragment. A GFP-AR expression Ho ,although the biological functions of PAK vector (pEGFP-AR) was similarly constructed in pEGFP-C1, However, abut using an Eagl site located eight amino acids from the N remain unclear, they likely differ in detail from most preterminus of the AR. To generate GST-PAK6 (256-681), an viously described PAKs based upon low-sequence Xhol site was introduced into the pGEX-2TK polylinker, and the entire PAK6 fragment from clone 56 was inserted in frame PAGE sample buffer, and labeled proteins were detected with using a compatible Sail site in pACT2 at the junction between a Phosphorlmager (Molecular Dynamics, Inc., Sunnyvale, the GAL4 activation domain and PAK6. CA EcoRI site at amino acid 256 in PAK6 and a Hindill site at the Center, Boston, MA) (81). For GTP loading, the GST-RacV12 3'-end. The fragment was then cloned at the 3'-end of VP16
and GST-Cdc42V12 fusion proteins bound to glutathione as an EcoRI-Hindll fragment. The reporter plasmids were an agarose beads (5 JAg) were initially incubated in 20 mM Tris, androgen-responsive luciferase reporter construct driven by pH 7.5, 100 mm NaCI, 1 mm EDTA, and 1 mM dithiothreitol (DTI), with a 1 0-fold molar excess of GTP-yS, for 15 min at 30 synthetic AREs and a minimal promoter (ARE 4 -luciferase) or MMTVpA3Luc, driven by the androgen-responsive MMTV-C. The beads were then placed on ice, and MgCI 2 was added LTR (83). The ARE 4 -luciferase reporter was constructed by to a concentration of 5 mM. After 5 ma on ice, the beads were inserting four tandem ARE repeats (5'-TGTACAGGATGTpelleted and lysates were added. GTP loading was compa-TCTGAATTCCATGTACAGGATGTTCT-3') in front of an Elb rable for the Rac and Cdc42 fusion proteins, based upon minimal TATA box sequence, followed by a firefly luciferase For GST pull-down experiments, CV1 cells were transgene. After the 24-h transfection, cells were cultured for fected in 10-cm plates with 10 jig of PAK6 in pcDNA3.1(-)/ another 24 h in DMEM with 5% CDS FCS, with or without Myc-His C, using Lipofectamine according to the manufacadded 10 nM DHT. Lysates were assayed for luciferase turer's directions (Life Technologies, Inc., Gaithersburg, MD). activity and Renilla activity using a dual luciferase kit (Promega Corp.), and luciferase activity was normalized for Transfected CV1 cells or LNCaP prostate carcinoma cells Renilla to give relative light units. (with endogenous AR) were lysed in 50 mM Tris, pH 7.6, 150
ERet transcriptional activity was assessed similarly using a mm NaCI, 5 mM MgCI 2 , 0.5% Triton X-100, 5 mm DTT, and protease inhibitors for 15 min at 4 C, followed by centrifugapcDNA3.1-ERa expression vector and a luciferase reporter tion to remove nuclei. Lysates were then incubated with OST gene, ERE 2 TK-Luc, regulated by two copies of the ERE from fusion topremoveinsu(5ei.g e p wherete indcuated)bnd with guthe vitellogenin gene (kindly provided by Myles Brown, Dana fusion proteins (5 Jug except where indicated) bound to gluFarber Cancer Institute). The ERa experiments were done in tathione agarose beads for 2-4 h at 4 C, followed by washes Fnrer medium. All p ernts were done in in lysis buffer and elution in SDS-PAGE samplebuffer. In the phenol red-free medium. All points were in triplicate or quadindiate exerientslyss ad wshe wer in10 M Tis, ruplicate and mean -± SEM are shown. Indicated experiments lysis and washes were in 10 mm Tris, Additional experiments used CV1 cells containing an intepH 7.5, 150 mm NaCI, 1 mm MgCI 2 , 1 mm EGTA, 1 mm DTT, grated luciferase reporter gene regulated by the androgen 10% glycerol, 0.1% Triton X-100, and protease inhibitors responsive MMTV-LTR. These CV1(MM1V-Luc) cells were (glycerol lysis buffer). PAK6 was detected by immunoblotting gensive by -TR . These CV ( cells w ere withmoue ati-yc mb 910,andAR ws dteced ith generated by transfecting CV1 cells with an MMTV-LTRwith mouse anti-myc mAb 9E10, and AR was detected with luciferase reporter plasmid (MMTVpA3Luc) (83) and neomya mixture of rabbit anti-AR antibodies against N and Cc resistance plasmid, and selecting for G418-resistant cells. terminal peptides (all from Santa Cruz Biotechnology, Inc., A series of clones were then screened to identify ones with Santalow background luciferase activity and high level androgen- 
